Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines: Part II

Dear Colleagues,  

A novel strain of coronavirus, SARS-CoV-2, the causative agent of the coronavirus disease (COVID-19), was first identified in late 2019 and triggered a pandemic, which has been ongoing since March 2020. The pandemic has already had a serious impact on the global economy and has resulted thus far in over 2 million deaths and almost 100 million infections. The development of effective therapeutics is an urgent global priority to stop the spread of COVID-19 infections and prevent further fatalities. As such, a number of platforms, such as drugs, vaccines, monoclonal antibodies, pharmacological therapy, plasma therapy, immune boosters, and alternative medicines, have been explored. Researchers are fast-tracking this process, and there have already been significant developments during preclinical and clinical phases in a relatively short period. There are a number of drug candidates and vaccines that have been developed for emergency use within a year, which is unprecedented in human history. 

In this Special Issue of Biologics, the focus will be on the development of vaccines, pharmacological therapy, alternative medicines, monoclonal antibodies, plasma therapy, preclinical studies, clinical trials, replication, viral life cycles, and the pathogenesis of SARS-CoV-2, as well as areas of identification of novel drug targets and any form of treatment models against COVID-19 infection. In vitro, in vivo, in silico, preclinical, and clinical trials are all welcome. 

This Special Issue will include reviews or original research papers on biologics against the SARS-CoV-2 virus/COVID-19. 

Prof. Dr. Vasso Apostolopoulos
Dr. Majid Davidson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• COVID-19
• SARS-CoV-2
• vaccine
• immunotherapies
• novel drugs
• pharmacological therapy
• monoclonal antibodies
• alternative medicine
• naturaceuticals
• pathogenesis